DailyIQ
|
Sector:HealthcareAll sectors
Last updated 6 minutes ago

IDXX·IDEXX Laboratories, Inc.

$.
+. (+.%)
After Hours
High
$573.02
Open
$561.93
Market Cap
44.53B
52W High
$769.98
Low
$559.72
P. Close
$563.65
P/E
40.66
52W Low
$506.91
Fwd P/E
34.11
DailyIQ Est.
$734.21
Technical Score (1D)
55
BUY
News Sentiment
70
BULLISH
Argus Research has just lifted its target price for IDXX to $627, citing a stronger earnings outlook, increased market share in diagnostics, and a promising product pipeline. This upgrade signals renewed confidence that the company can expand revenue and improve margins, which could lift short‑term trading sentiment. The upgrade follows an earlier downgrade to $579, so the market is now seeing a reversal in analyst sentiment that may influence near‑term volatility. A comparison with ALC highlights IDXX’s stronger earnings growth and lower P/E ratio, suggesting it may offer better value for growth‑focused investors. Both the target‑price change and the valuation comparison point to the upcoming earnings release as the key catalyst for the next 1–10 trading days. SeekingAlpha’s hold rating notes that the current premium valuation already assumes increased tests per veterinary visit, not just more visits, and flags regulatory changes and competition as risks that could materialize in the earnings report. The company’s Q2 2026 earnings will be released on August 4, 2026, with an analyst conference call at 8:30 a.m. ET, providing the first opportunity to assess whether the earnings trajectory and guidance align with the upgraded outlook. Option market data shows a rise in open interest for IDXX call contracts and higher implied volatility, indicating that traders are positioning for a potential move around the earnings announcement. Therefore, watch the earnings call for guidance, test‑volume data, and any regulatory updates, and monitor option expiry dates for signs of short‑term price swings.
Earnings Summary
IDEXX Laboratories, headquartered in Westbrook, Maine, is a global provider of diagnostic and information technology solutions for the animal health and water testing industries, focusing on in‑clinic instruments, rapid assays, and reference services for companion animals and livestock. Operating within the healthcare diagnostics sector, the company leverages a broad product suite to enhance animal health outcomes and water safety data. In the most recent earnings cycle, IDEXX reported Q1 2026 EPS of $3.47 versus an estimate of $3.92, a miss after a string of five consecutive beats, while revenue rose to $1.140 billion from $1.090 billion in Q4 2025, reflecting a modest 4.5% increase. Compared to the prior two quarters (Q1 2025 EPS $2.96, revenue $998 million; Q2 2025 EPS $3.63, revenue $1.109 billion), the company’s EPS growth slowed from a 22% year‑over‑year jump in Q2 2025 to a 15% rise in Q1 2026, and revenue growth decelerated from 10% in Q2 2025 to 4.5% in Q1 2026, indicating a potential plateau in top‑line momentum. Historically, IDEXX has maintained a strong earnings beat record—six of the last seven quarters exceeded analyst expectations—yet revenue growth has occasionally lagged behind EPS, suggesting margin expansion or pricing power. Recent analyst commentary from Argus Research highlights a target‑price lift to $627, driven by expectations of increased test volumes per veterinary visit and potential regulatory approvals that could open new markets; the upgrade underscores confidence in the company’s product pipeline but also flags competition and regulatory risk as key concerns. Investors should watch the upcoming Q2 2026 earnings call for guidance on test‑volume trends, any updates on regulatory approvals, and commentary on competitive dynamics, as these factors will likely influence the company’s valuation and short‑term price volatility.

EPS

EstBeatMiss
$2.68$3.04$3.39$3.75$4.10Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.94 - -
Q1'26$3.92$3.47-11.6%
Q4'25$2.99$3.08+3.1%
Q3'25$3.14$3.40+8.3%
Q2'25$3.30$3.63+10.0%
Q1'25$2.85$2.96+3.9%

Revenue

EstBeatMiss
$965M$1.0B$1.1B$1.2B$1.3BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.2B - -
Q1'26$1.2B$1.1B-4.8%
Q4'25$1.1B$1.1B-0.3%
Q3'25 - $1.1B -
Q2'25 - $1.1B -
Q1'25 - $998M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

IDXX Stock Snapshot

IDXX is currently trading at $563.57, giving IDEXX Laboratories, Inc. a market cap of 44.53B and a P/E ratio of 40.7. Today's range spans $559.72–$573.02, with shares opening at $561.93 and moving down $0.08 (0.0%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD) with a news sentiment reading of 70/100.

Over the past year IDXX has traded between $506.91 and $769.98 - the current price is +11.2% off the 52-week low and -26.8% from the high. 24 analysts cover the stock with a Hold consensus and a mean 12-month target of $709.14 (range $470.00–$805.00), implying upside of +25.8%.

For fundamental investors, IDXX's neutral technical phase (55/100, HOLD) is an opportunity to assess valuation without the noise of trending price action. At 44.53B in Healthcare market cap The current P/E ratio stands at 40.7., bullish sentiment (70/100) and a price of $563.57 (in the lower half of its 52-week range) describe a stock where the primary value driver is fundamental rather than momentum. Annual range: $506.91–$769.98.

In neutral phases, large-cap Healthcare names like IDXX are often where sector rotation debates play out quietly — at 44.53B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 55/100 (HOLD) and bullish sentiment (70/100) at $563.57 (in the lower half of its 52-week range) describe a stock that is being considered rather than avoided.